Your browser doesn't support javascript.
loading
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.
Salwender, Hans; Weinhold, Niels; Benner, Axel; Miah, Kaya; Merz, Maximilian; Haenel, Mathias; Jehn, Christian; Mai, Elias; Menis, Ekaterina; Blau, Igor; Scheid, Christof; Hose, Dirk; Seckinger, Anja; Luntz, Steffen; Besemer, Britta; Munder, Markus; Brossart, Peter; Glass, Bertram; Lindemann, Hans-Walter; Weisel, Katja; Hanoun, Christine; Schnitzler, Paul; Klemm, Sarah; Goldschmidt, Hartmut; Raab, Marc; Elmaagacli, Ahmet.
Affiliation
  • Salwender H; Department of Oncology and Hematology, Asklepios Hospital Hamburg Altona, Hamburg, Germany.
  • Weinhold N; Department of Oncology and Hematology, Medizinische Klinik Heidelberg, Heidelberg, Germany.
  • Benner A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
  • Miah K; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
  • Merz M; Department of Hematology and Cell Therapy, University Hospital Leipzig, Leipzig, Germany.
  • Haenel M; Department of Oncology and Hematology, Klinikum Chemnitz, Chemnitz, Germany.
  • Jehn C; Department of Hematology/Oncology and Stem Cell Transplantation, AK St. Georg, Hamburg, Germany.
  • Mai E; Department of Oncology and Hematology, Medizinische Klinik Heidelberg, Heidelberg, Germany.
  • Menis E; Department of Oncology and Hematology, Medizinische Klinik Heidelberg, Heidelberg, Germany.
  • Blau I; Department of Oncology and Hematology, Charité Universitätsmedizin, Berlin, Germany.
  • Scheid C; Department of Oncology and Hematology, University Hospital Cologne, Cologne, Germany.
  • Hose D; Laboratory of Hematology and Immunology & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.
  • Seckinger A; Laboratory of Hematology and Immunology & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.
  • Luntz S; Department of Oncology and Hematology, Coordination Centre for Clinical Trials (KKS), Heidelberg, Germany.
  • Besemer B; Department of Oncology and Hematology, University Hospital Tubingen, Tubingen, Germany.
  • Munder M; Department of Oncology and Hematology, University Medical Center Mainz, Mainz, Germany.
  • Brossart P; Department of Oncology and Hematology, University Hospital Bonn, Bonn, Germany.
  • Glass B; Department of Oncology and Hematology, Helios Hospital Berlin Buch, Buch, Germany.
  • Lindemann HW; Department of Oncology and Hematology, Kath. Krankenhaus Hagen, Hagen, Germany.
  • Weisel K; Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Hanoun C; Department of Oncology and Hematology, University Hospital Essen, Essen, Germany.
  • Schnitzler P; Zentrum für Infektiologie, Virologie Universitätsklinikum Heidelberg, Heidelberg, Germany.
  • Klemm S; Zentrum für Infektiologie, Virologie Universitätsklinikum Heidelberg, Heidelberg, Germany.
  • Goldschmidt H; Department of Oncology and Hematology, Medizinische Klinik Heidelberg, Heidelberg, Germany.
  • Raab M; Department of Oncology and Hematology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Elmaagacli A; Department of Oncology and Hematology, Medizinische Klinik Heidelberg, Heidelberg, Germany.
Hematology ; 29(1): 2320006, 2024 Dec.
Article in En | MEDLINE | ID: mdl-38407192
ABSTRACT

OBJECTIVES:

The seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous stem cell transplantation remains unknown.

METHODS:

Here, we analyzed the CMV immunoglobulin (Ig) serology of 446 newly-diagnosed multiple myeloma (MM) patients of the GMMG-MM5 phase III trial with a median follow-up of 58 months.

RESULTS:

CMV IgG and IgM positivity was seen in 51% and 6% of the patients, respectively. In multivariate analysis CMV IgG and CMV IgM serology show an age-depending effect for PFS. We identified positive CMV IgG/positive CMV IgM serology as an age-depending beneficial factor on PFS.

DISCUSSION:

Younger patients with a positive CMV IgG/positive CMV IgM serology experienced a favorable effect on PFS, whereas a positive CMV IgG/positive CMV IgM serology at older age has a disadvantageous effect on PFS.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cytomegalovirus Infections / Hematopoietic Stem Cell Transplantation / Multiple Myeloma Limits: Humans Language: En Journal: Hematology Journal subject: HEMATOLOGIA Year: 2024 Document type: Article Affiliation country: Germany Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cytomegalovirus Infections / Hematopoietic Stem Cell Transplantation / Multiple Myeloma Limits: Humans Language: En Journal: Hematology Journal subject: HEMATOLOGIA Year: 2024 Document type: Article Affiliation country: Germany Country of publication: United kingdom